For what it's worth, other Biontech Scanner stocks have done remarkably well including $VKTX $DAWN and $AUR. His two top stocks are next up $AQST and $IOVA.
$VSTM reports Q126 sales of its LGSOC combo Thursday after the close
For its 1st 2 full fiscal quarters post launch, sales of VSTM's combo therapy have tracked sales of CTIC's Vonjo & are handily higher than ZGNX's Fintepla. Both $CTIC & $ZGNX were acquired for enterprise values of $1.7B. If you believe actual product sales are a barometer, again a barometer, for valuation potential then investors should follow VSTM.
If VSTM's Q126 sales are on par or beat analyst estimates then it may affirm VSTM's LGSOC hypothetical M&A exit valuation could be on par with CTIC & ZGNX. Just remember VSTM fully diluted shares are roughly 20% higher.
We'll add a comparison to $DAWN Ojemda sales (VSTM running roughly 1/3 less but DAWN exited at ~$2.2B ish). The dots connect
VSTM has a 2nd asset showing genuine promise in solid tumors with a KRAS 12D mutation (very roughly 15% of all solid tumors, higher in some & lower in others). Updated data is due in Q226.
This is not investment advice. $XBI
$DAWN Servier completes the acquisition of Day One Biopharmaceuticals
https://www.prnewswire.com/news-releases/servier-completes-the-acquisition-of-day-one-biopharmaceuticals-302751627.html
$DAWN Equity Corporate Actions Alert #2026 - 254
Information Regarding the Tender Offer of Day One Biopharmaceuticals, Inc. (DAWN)
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-254
The tender offer by Servier to acquire all of the outstanding common stock of Day One Biopharmaceuticals, Inc. (DAWN) is scheduled to expire one minute after 11:59 p.m. ET, on April 22, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on April 23, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on April 22, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (April 23rd) and will be suspended effective April 24, 2026.
DAWN shareholders will receive $21.50 per share after closing.
Citizens🏁 $WHWK and said: We are initiating coverage of Whitehawk Therapeutics, Inc. with a Market Outperform rating and price target of $8 based on a cash per share and platform value analysis.
$ABBV $DAWN - Servier PFE LLY
Citizens added—Whitehawk is advancing three highly specific antibody- drug conjugates (ADCs) against clinically validated targets (PTK7, MUC16, SEZ6) with initial proof of concept data expected in 1H27.
With HWK-007 and HWK-016 advancing through a Phase 1 dose-escalation trial, an IND filing for HWK-206 on track for mid-2026, and a cash position of $145.7MM, we believe shares are attractive,
with 75% downside (bear case scenario is $1) and 150% upside (bull case scenario is $10).
$DAWN as this ticker fades into oblivion with the aquisition, I just wanted to shoutout my boy I_am_Sparta for the most stupid biotech takes. I hope he is doing ok, and found the time to study a bit the sector or maybe even get some internship at a pharma company or cro or some shit where he can learn the ropes
$SLNO M&A enterprise value of $2.44B appears to be priced @ the lowest Year 4 & 10-year revenue multiples in recent history (of course analyst estimates may not be credible).
SLNO was acquired for $0.2B more than DAWN's EV. Analysts forecast SLNO to generate roughly $10B more revenues over the next 10 years than $DAWN ?
SLNO was acquired for 1.7X FY29 (Year 4) analyst consensus. Centerview cited the lowest peer Year 4 M&A revenue multiple was 2.25X (though an oncology focused trx). See yesterday's post. We'd remind investors SLNO generated 99% gross margins on Vykat sales in FY25.
SLNO was acquired for 0.15X 10-year analyst consensus. We recall ZGNX & SWTX exiting at the lowest 10-year multiples of 0.25 & 0.26X, respectively. Most peer M&A exits are priced @ 0.30-0.40X 10-year revenues per the acquiree mgmt/BOD
$NBIX closed at 3.1X. If SLNO FY29 consensus is credible then, because no stock was issued, this s/b quite accretive to NBIX shareholders
This is not investment advice
$XBI $IBB
$DAWN filed their 14D9 filing with the SEC on 3/26/26 that includes, among other things, the DAWN financial/revenue forecast prepared by DAWN mgmt/BOD & provided Servier. We assume Servier assessed this forecast when they agreed to acquire DAWN for an enterprise value of roughly $2.16B.
The attachment compares the DAWN mgmt/BOD prepared revenue forecast to DAWN analyst consensus revenue estimates as of 3/6/26 (the day the M&A exit was announced). DAWN mgmt/BOD forecasts were, more or less, consistent with analysts for Year 1 - 5 (FY26-30) where Year 6 - 10 (FY31-35) mgmt/BOD revenues were forecast roughly 15-20% higher than analysts. This is consistent with peer comm'l-stage oncology focused M&A (BPMC/SWTX etc).
Where DAWN was acquired for 0.35X 10-year analyst consensus, DAWN was acquired for 0.29X 10-year revenues per DAWN mgmt/BOD.
Other comm'l-stage oncology focused M&A candidates (again candidates) with a gross margin profile consistent with Ojemda include
$SNDX
$URGN
$IMCR
$NUVB
It was 1 year ago today $SLNO got approval for Vykat.
SLNO's multiples suggest SLNO is severely undervalued if, and this is a GARGANTUAN if, but if analyst consensus revenue estimates are credible.
For perspective, the attachment compares SLNO 7-year analyst consenses to the 7 year revenue forecasts prepared by the mgmt/BOD of 10 peer commercial-stage bios acquired within 15 months of FDA approval.
Note analysts forecast SLNO to generate more revenues over the next 7 years than RETA mgmt/BOD forecast when $RETA was acquired for an enterprise value of ~$7.0B. RETA mgmt/BOD projected 91% gross margins where SLNO FY25 gross margin was 98%.
By itself, does this not suggest SLNO is deeply undervalued. Recall $DAWN traded for virtually no enterprise value last summer & was just acquired for over $2B
This is not investment advice. We do not understand Vykat's clinical value proposition, risk nor whether it's worth peer multiples.
$XBI $IBB
